News from jazz pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 15, 2023, 07:00 ET Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American...

Mar 01, 2023, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2022 and provided financial...

Mar 01, 2023, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2022 and provided financial...

Feb 27, 2023, 16:15 ET Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor conferences: Cowen 43rd...

Feb 15, 2023, 16:15 ET Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full year financial results on Wednesday,...

Jan 19, 2023, 07:45 ET Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, ...

Jan 03, 2023, 07:30 ET Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan...

Dec 21, 2022, 07:30 ET Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its...

Dec 05, 2022, 08:00 ET Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) today announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex ®)...

Nov 28, 2022, 08:09 ET Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including...

Nov 18, 2022, 13:00 ET Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental Biologics License...

Nov 09, 2022, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total...

Nov 09, 2022, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total...

Nov 03, 2022, 10:43 ET Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts will be presented at the American Society of Hematology (ASH) Annual...

Nov 01, 2022, 16:15 ET Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences: Jefferies...

Oct 26, 2022, 16:15 ET Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial results on Wednesday, November 9, 2022,...

Oct 19, 2022, 06:00 ET Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50...

Aug 31, 2022, 16:15 ET Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences: Citi's 17th ...

Aug 18, 2022, 07:30 ET Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex®...

Aug 03, 2022, 16:05 ET Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and...

Jul 20, 2022, 16:15 ET Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022,...

Jun 28, 2022, 07:30 ET Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial (NCT04657666) evaluating nabiximols...

Jun 07, 2022, 07:30 ET Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with...

Jun 01, 2022, 16:15 ET Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June...

Jun 01, 2022, 07:45 ET Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its neuroscience...